Annual Report 2024

CHAIRMAN’S STATEMENT 6 The United Laboratories International Holdings Limited Annual Report 2024 Dear Shareholders, In 2024, while the external environment was complex and volatile, China’s economy ran steadily and made steady progress. The past year was a critical year for the country to realize the objectives and tasks of the 14th Five-Year Plan, in which policies for the pharmaceutical industry were introduced intensively. Driven by policy guidance and market demand, the pharmaceutical industry has continued to deepen its reforms, and the competitive landscape of the market has undergone profound changes, bringing about new development dynamics and creating both opportunities and challenges. Facing changes in the industry, we have proactively adapted to the new situation and continued to forster the research and development of new drugs, production and supply, marketing services and other work, achieving gratifying results. On behalf of the board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company” or “The United Laboratories”), I am pleased to present to our shareholders and partners from all sectors of society the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2024 (the “Year”). In the course of the year, the Group recorded revenue of approximately RMB13,758.9 million, which kept stable to 2023. Profit attributable to owners of the Company was RMB2,659.7 million, representing a year-on-year slightly decrease of 1.5%. Earnings per share were RMB146.39 cents. The Board recommends the payment of a final dividend of RMB28 cents per share and a special dividend of RMB12 cents per share for the year ended 31 December 2024. The dividend for the full year was RMB56 cents together with the distributed interim dividend of RMB16 cents per share, representing a dividend payout ratio of 38.3%. Mr. Tsoi Hoi Shan Chairman